Launch of the EAACI Guidelines – Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old
7759
11m7
Share
We are proud to announce the launch of the new EAACI Guidelines on Omalizumab for the treatment of Chronic Spontaneous Urticaria, a major scientific output of 2021 for the Academy.
Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1R-antihistamines.
Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification.
The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.
These new Guidelines offer a desk reference tool for healthcare providers, patients, regulators and healthcare systems, based on a critical appraisal of the current evidence and a structured approach in formulating recommendations in alignment with the key principles of personalized medicine and implementation science.
We encourage you to read, share and utilize these guidelines broadly, to contribute in standardising best practices in the field.
Ioana Agache
Chair of Biologicals Guidelines
Marek Jutel
Chair of Biologicals Guidelines
Oscar Palomares
Chair of Biologicals Guidelines
Last updated 30 July 2021
